Core Labs Jumps 79% in 6 Months: Time to Buy or Stay on the Sidelines?
Core Laboratories Inc. (CLB) has seen a significant 79% stock increase in the past six months, outperforming its sub-industry and sector due to strong international demand, consistent shareholder returns, a robust balance sheet, and an asset-light business model. However, the company faces near-term headwinds from U.S. onshore activity, margin compression from tariffs and raw material costs, dependence on client success, and valuation concerns, leading Zacks to rate the stock as a "Hold." Investors are advised to wait for a more opportune entry point, while other related companies like TechnipFMC (FTI), Oceaneering International (OII), and USA Compression Partners (USAC) are rated as "Buy."
Core Laboratories (NYSE:CLB) Shares Pass Above 200 Day Moving Average - Should You Sell?
Core Laboratories (NYSE:CLB) shares recently surpassed their 200-day moving average, trading at $18.5580 with a 200-day average of $14.71. The company reported better-than-expected earnings for the last quarter and announced a quarterly dividend. Analysts currently rate the stock as "Hold" with an average target price of $12.50.
Core Laboratories Q4 Earnings Beat Estimates, Expenses Increase Y/Y
Core Laboratories (CLB) reported fourth-quarter 2025 adjusted earnings of 21 cents per share, surpassing the Zacks Consensus Estimate, primarily due to strong performance in its Production Enhancement segment. Despite a year-over-year revenue increase of 7% to $138.3 million, total costs and expenses rose by 6.4%, and the company's Reservoir Description segment underperformed. CLB also provided an outlook for Q1 2026, anticipating revenue between $124 million and $130 million, with earnings per share projected to be between 11 and 15 cents.
Core Laboratories N.V. (NYSE:CLB) Q4 2025 Earnings Call Transcript
Core Laboratories N.V. (NYSE:CLB) announced its Q4 2025 earnings, with revenue up 3% quarter-over-quarter and 7% year-over-year, driven by strong international demand for proprietary technologies. The company emphasized its strategic plan focusing on technology investments, operational efficiency, and returning free cash to shareholders through dividends and share repurchases. Despite geopolitical conflicts and commodity price volatility, Core Lab maintains a constructive multi-year outlook, particularly for international and offshore exploration, while acknowledging a flattening of US onshore production growth.
Core Laboratories Q4 Earnings Beat Estimates, Expenses Increase Y/Y
Core Laboratories (CLB) reported Q4 2025 adjusted earnings of 21 cents per share, exceeding the Zacks Consensus Estimate of 20 cents, largely due to strong performance in its Production Enhancement segment. Despite beating revenue estimates with $138.3 million, the company's bottom line decreased year-over-year due to increased expenses and a weaker Reservoir Description segment. Core Laboratories provided an outlook for Q1 2026, anticipating revenues between $124 million and $130 million, and discussed its strategy in a volatile market for oil and gas services.
Core Laboratories Q4 Earnings Beat Estimates, Expenses Increase Y/Y
Core Laboratories (CLB) reported Q4 2025 adjusted earnings of 21 cents per share, surpassing the Zacks Consensus Estimate of 20 cents, driven by strong performance in its Production Enhancement segment. Despite the beat, the bottom line saw a slight year-over-year decrease due to increased expenses and underperformance in the Reservoir Description segment. The company also announced a quarterly cash dividend and provided an outlook for Q1 and the full year 2026, anticipating continued growth in international demand despite some U.S. land market softness and tariff pressures.
Core Laboratories Stock Under Pressure: Is This Energy Services Veteran a Contrarian Buy or a Value
Core Laboratories (CLB) stock has recently experienced a modest slide, causing investors to question if it's a contrarian buy or a value trap, despite a solid year-over-year gain. The stock's performance reflects a mixed technical picture and cautious bearish sentiment, with analysts largely holding neutral stances. Its future trajectory will depend on capital allocation trends in the energy sector, crude oil prices, CLB's execution on cost control, and the growing commercial traction of its involvement in the energy transition.
Core Laboratories outlines Q1 2026 guidance of $124M–$130M revenue amid strong international demand and cost challenges
Core Laboratories (NYSE: CLB) announced its guidance for Q1 2026, projecting revenues between $124 million and $130 million. This outlook is driven by increasing international activity, particularly in the Eastern Hemisphere, which is expected to represent over half of the company's revenue for the first time in a decade. Despite strong demand, the company anticipates continued cost challenges related to labor and supply chain issues.
Core Lab (CLB) Q4 2025 Earnings Call Transcript
Core Laboratories (CLB) reported modest revenue growth in Q4 2025, driven by international demand and advanced technologies, despite geopolitical disruptions, tariffs, and weather challenges. The company emphasized its commitment to shareholder returns through dividends and share repurchases, while projecting a seasonal dip in Q1 2026. Management highlighted a long-term constructive outlook, focusing on international exploration and field development, cost discipline, capital allocation, and technological innovation.
Core Laboratories Inc. (NYSE:CLB) Declares Quarterly Dividend of $0.01
Core Laboratories Inc. (NYSE:CLB) announced a quarterly dividend of $0.01 per share, payable March 9th to shareholders of record on February 16th, with an ex-dividend date of February 13th. The company's Q4 earnings surpassed expectations with EPS of $0.21 and revenue of $138.3M, despite shares sliding 9.8% after the announcement. Analysts project $0.96 EPS for the current year, and the company has a low dividend payout ratio of 4.7%.
Earnings Flash (CLB) Core Laboratories Inc. Posts Q4 Adjusted EPS $0.21 per Share, vs. FactSet Est of $0.19
Core Laboratories Inc. (CLB) reported adjusted earnings per share of $0.21 for the fourth quarter, surpassing FactSet's estimate of $0.19. The company also announced that it expects first-quarter revenue to be between $124 million and $130 million. Additionally, Core Laboratories Inc. approved a cash dividend payable on March 9, 2026.
Core Laboratories: Fourth Quarter Earnings Overview
Core Laboratories Inc. announced its fourth-quarter financial results, reporting a net profit of $7.1 million and adjusted earnings of $0.21 per share. The energy services provider generated $138.3 million in revenue for the quarter. For the full year, the company posted a total profit of $31.8 million on annual revenue of $526.5 million.
Earnings Flash (CLB) Core Laboratories Inc. Reports Q4 Revenue $138.3M, vs. FactSet Est of $132.1M
Core Laboratories Inc. (CLB) has reported its Q4 revenue at $138.3 million, surpassing the FactSet estimate of $132.1 million. This earnings flash also notes that the company posted Q4 Adjusted EPS of $0.21 per share, exceeding the FactSet estimate of $0.19. Additionally, Core Laboratories expects Q1 revenue to be between $124 million and $130 million.
Core Laboratories posts Q4 2025 results and dividend
Core Laboratories (CLB) announced its Q4 2025 results, reporting a 7% year-over-year revenue increase to $138.3 million and a $0.01 per share quarterly dividend. The company reduced debt and repurchased shares, driven by international demand for its services despite softer U.S. land activity. TipRanks' AI Analyst rated CLB as "Outperform," recognizing its financial health and strategic initiatives amidst geopolitical risks and valuation concerns.
Core Laboratories: Fourth Quarter Earnings Overview
Core Laboratories Inc. announced its financial results for the fourth quarter, reporting a net profit of $7.1 million and earnings of $0.15 per share, with adjusted earnings reaching $0.21 per share. The energy services provider generated $138.3 million in revenue for the quarter. For the full year, the company achieved a total profit of $31.8 million with $526.5 million in annual revenue.
Investors in Core Laboratories (NYSE:CLB) have unfortunately lost 47% over the last five years
Core Laboratories Inc. (NYSE:CLB) shareholders have experienced a significant 48% loss over the past five years, despite an 18% gain in the last three months. While the company became profitable within this five-year period and revenue grew by 2.3% annually, the share price has not reflected these improvements. Investors are advised to look closer at the fundamentals and consider analyst forecasts to understand the discrepancy between business performance and stock valuation.
What's in Store for Core Laboratories Stock in Q4 Earnings?
Core Laboratories Inc. (CLB) is scheduled to announce its Q4 2025 earnings on February 4, with a Zacks Consensus Estimate of 20 cents per share and $132 million in revenue. The article forecasts an increase in revenues driven by strong performance in its Reservoir Description and Production Enhancement segments, despite an anticipated rise in operating expenses. The Zacks model, however, does not conclusively predict an earnings beat for CLB, which currently holds a Zacks Rank #3.
What's in Store for Core Laboratories Stock in Q4 Earnings?
Core Laboratories (CLB) is scheduled to release its fourth-quarter 2025 earnings on February 4th, with analysts anticipating a profit of 20 cents per share on revenues of $132 million. The company's prior quarter saw an earnings beat due to increased demand for its services in international regions. While revenues are expected to rise year-over-year, appreciation in operating costs may negatively impact the bottom line, and the Zacks model does not conclusively predict an earnings beat for CLB in this quarter.
Core Laboratories (NYSE:CLB) Shares Cross Above Two Hundred Day Moving Average - Here's Why
Core Laboratories (NYSE:CLB) stock has recently crossed above its 200-day moving average, trading at $19.45, significantly higher than its $13.82 average. Despite this, analysts maintain a "Hold" rating with an average target price well below the current market price. The company reported strong Q4 2025 guidance and institutional investors show high ownership, with several firms increasing their stakes, indicating confidence in the company's prospects.
CORE LABORATORIES ANNOUNCES TIMING OF FOURTH QUARTER 2025 EARNINGS RELEASE AND CONFERENCE CALL
Core Laboratories (NYSE: "CLB") announced the timing for its fourth quarter 2025 earnings release and conference call. The call is scheduled for February 5, 2026, at 7:30 a.m. CST / 8:30 a.m. EST, with financial and operational results to be discussed by leadership. The earnings press release will be issued on February 4, 2026, after market close.
Is Core Laboratories Inc.'s (NYSE:CLB) Recent Stock Performance Tethered To Its Strong Fundamentals?
Core Laboratories (NYSE:CLB) has seen its stock price increase significantly by 50% in the last three months, prompting an examination of its fundamentals. The company boasts a healthy 12% Return on Equity (ROE) and has demonstrated a strong 43% net income growth over the past five years, exceeding the industry average. This performance is supported by a low payout ratio of 6.3%, indicating significant reinvestment of profits back into the business.
Oilfield services firm Core Laboratories sets early Q4 earnings call
Core Laboratories (NYSE: CLB) announced it will release its fourth-quarter 2025 earnings after market close on February 4, 2026, followed by a conference call on February 5, 2026, at 7:30 a.m. CST / 8:30 a.m. EST. Chairman and CEO Larry Bruno, CFO Chris Hill, and SVP Gwen Gresham will discuss financial and operational results. The company provides reservoir description and production enhancement services globally.
CORE LABORATORIES ANNOUNCES TIMING OF FOURTH QUARTER 2025 EARNINGS RELEASE AND CONFERENCE CALL
Core Laboratories (NYSE: "CLB") announced that it will host its fourth quarter 2025 conference call for investors and analysts on February 5, 2026, at 7:30 a.m. CST / 8:30 a.m. EST. An earnings press release will be available after market close on February 4, 2026, on the Company's website. The call will feature Chairman and CEO Larry Bruno, CFO Chris Hill, and SVP Gwen Gresham discussing financial and operational results; a replay and transcript will also be made available online.
CORE LABORATORIES ANNOUNCES TIMING OF FOURTH QUARTER 2025 EARNINGS RELEASE AND CONFERENCE CALL
Core Laboratories (NYSE: "CLB") will host its fourth quarter 2025 conference call for investors and analysts on February 5, 2026, at 7:30 a.m. CST / 8:30 a.m. EST. An earnings press release will precede this, issued after market close on February 4, 2026, and will be accessible via the company's website. The call will discuss financial and operational results, with a replay and transcript available online afterward.
The Truth About Core Laboratories Inc (CLB): Quiet Boomer Stock or Next Big Energy Rebound Play?
Core Laboratories Inc (CLB) is presented as a low-key energy tech company that might be a sleeper rebound story for investors interested in the oil and gas sector. While not a viral stock, it focuses on helping energy companies optimize reservoir performance. The article evaluates CLB's potential as a value play for high-conviction energy investors, comparing its niche specialist approach against larger competitors and advising caution due to sector cyclicality.
Ariel Investments LLC Has $149.49 Million Stock Position in Core Laboratories Inc. $CLB
Ariel Investments LLC significantly increased its stake in Core Laboratories Inc. (NYSE:CLB) by 25.5% in the second quarter, bringing its total holdings to 12,976,463 shares valued at approximately $149.49 million. This makes Core Laboratories the 28th largest position in Ariel Investments' portfolio, representing about 1.7% of its total investments. Other institutional investors have also adjusted their positions in CLB, and analysts currently rate the stock as a "Hold" with an average target price of $12.50.
Fisher Asset Management LLC Sells 143,838 Shares of Core Laboratories Inc. $CLB
Fisher Asset Management LLC reduced its stake in Core Laboratories Inc. by 14.2%, selling 143,838 shares, though other institutional investors increased their holdings. Core Laboratories recently surpassed quarterly earnings estimates, with the stock trading up and analysts maintaining a "Hold" rating with a $12.50 target. The company also declared a quarterly dividend of $0.01 per share.
P/E Ratio Insights for Core Laboratories
Core Laboratories Inc. (NYSE: CLB) is currently trading at $14.95, reflecting recent stock decreases. The company's P/E ratio of 22.12 is higher than the Energy Equipment & Services industry average of 21.78, suggesting it may be overvalued or expected to perform better in the future. Investors should consider the P/E ratio alongside other financial metrics and industry trends for a comprehensive analysis.
Raiffeisen Bank International AG Sells 44,977 Shares of Core Laboratories Inc. $CLB
Raiffeisen Bank International AG significantly reduced its stake in Core Laboratories Inc. (NYSE:CLB) by selling 44,977 shares, representing a 42.8% decrease in its holdings. Following this sale, the institutional investor now owns 60,000 shares of the oil and gas company, valued at approximately $682,000. Core Laboratories recently reported strong quarterly earnings, surpassing analyst estimates, and has a consensus "Hold" rating with a price target of $12.50.
Campbell & CO Investment Adviser LLC Takes Position in Core Laboratories Inc. $CLB
Campbell & CO Investment Adviser LLC acquired a new position in Core Laboratories Inc. (NYSE:CLB) during the second quarter, purchasing 25,831 shares valued at approximately $298,000. Several other institutional investors also adjusted their holdings in CLB, and the article provides an overview of recent analyst ratings, stock performance, and financial results for Core Laboratories Inc.
Advisors Capital Management LLC Buys 36,196 Shares of Core Laboratories Inc. $CLB
Advisors Capital Management LLC significantly increased its stake in Core Laboratories Inc. by 15.2% in Q2, acquiring 36,196 additional shares and now holding 275,063 shares valued at approximately $3.17 million. This move comes as other institutional investors have also adjusted their holdings, with analysts maintaining a consensus "Hold" rating and a $12.50 price target for CLB. Core Laboratories recently surpassed quarterly earnings and revenue estimates and announced a Q4 2025 EPS guidance, alongside a quarterly dividend payment.
Fox Run Management L.L.C. Makes New Investment in Core Laboratories Inc. $CLB
Fox Run Management L.L.C. recently acquired a new stake in Core Laboratories Inc. (NYSE:CLB), purchasing 17,493 shares valued at approximately $202,000. Several other institutional investors also adjusted their holdings, with Ariel Investments LLC significantly increasing its stake to over 10 million shares. Core Laboratories reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend, while analysts maintain a "Hold" rating for the stock.
Precision Trading with Core Laboratories Inc. (CLB) Risk Zones
This article from Stock Traders Daily analyzes Core Laboratories Inc. (CLB) with a focus on risk zones and trading strategies. It highlights weak sentiment across all horizons, supporting a short bias, and provides institutional trading strategies for various risk profiles. The analysis includes AI-generated signals for support and resistance levels across different timeframes.
Trading the Move, Not the Narrative: (CLB) Edition - news.stocktradersdaily.com
This article provides an AI-driven analysis for Core Laboratories Inc. (NYSE: CLB), highlighting a potential shift from persistent mid and long-term weakness to stronger near-term sentiment. It outlines three distinct institutional trading strategies—Position Trading LONG, Momentum Breakout, and Risk Hedging SHORT—with specific entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for CLB.
Core Laboratories to Post Q3 Earnings: Key Metrics to Watch - TradingView
Core Laboratories (CLB) is preparing to release its Q3 2025 earnings on October 22, with analysts expecting 19 cents per share on $127.5 million in revenue, a decline from the prior year. Despite potential revenue challenges due to geopolitical conflicts and volatile commodity prices, the company anticipates a rebound in laboratory services and continued progress in strategic objectives. The Zacks model predicts an earnings beat for CLB, which currently holds a Zacks Rank #3, due to a positive Earnings ESP.
Core Laboratories (CLB) to Release Earnings on Wednesday - Defense World
Core Laboratories (CLB) is scheduled to release its earnings on Wednesday. The company recently declared a quarterly dividend of $0.01 and institutional investors own a significant portion of its stock. Analysts have recently set "hold" ratings for CLB with various price targets.
Strength Seen in Core Laboratories (CLB): Can Its 6.0% Jump Turn into More Strength? - Yahoo Finance
Core Laboratories (CLB) experienced a 6% increase in its stock price due to a rebound in global oil prices and renewed optimism over U.S.-China trade talks. The rise was also supported by positive data on Chinese crude imports, stable OPEC demand forecasts, and hopes for Middle East peace, all benefiting oilfield service companies. Despite this jump, the consensus EPS estimate for the upcoming quarter remains unchanged, suggesting investors should monitor future earnings estimate revisions for sustained strength.
Core Laboratories (CLB) Falls Amid Escalating Trade Tensions - Insider Monkey
Core Laboratories Inc. (CLB) experienced a significant share price drop of 14.91% between October 3 and October 10, 2025, primarily due to escalating trade tensions between the US and China, which led to a decline in crude oil prices. Despite this downturn, the company recently acquired Solintec, strengthening its position in the Brazilian oil and gas market. The article also touches upon investment opportunities in AI stocks, suggesting they might offer higher returns and lower risk than CLB.
Core Laboratories (CLB) Falls Amid Escalating Trade Tensions
Core Laboratories Inc. (CLB) experienced a significant 14.91% share price drop between October 3 and October 10, 2025, driven by escalating trade tensions between the US and China. These tensions led to a decline in crude oil prices, impacting the oil and gas industry. Despite the downturn, Core Labs recently acquired Solintec, strengthening its position in the Brazilian oil and gas market, but its share price is still down over 43% since the beginning of 2025.
Core Laboratories (CLB) Falls Amid Escalating Trade Tensions
Core Laboratories Inc. (CLB) saw its share price drop by 14.91% between October 3 and October 10, 2025, due to escalating US-China trade tensions and their impact on crude oil prices. Despite this downturn and a year-to-date decline of over 43%, the company recently acquired Solintec, a geological services firm, to strengthen its position in the Brazilian oil and gas market. The article suggests considering undervalued AI stocks for greater upside potential and less downside risk.
Major Oil Services Expansion: Core Labs Acquires Brazil's Leading Geological Lab Solintec for Pre-Salt Analysis
Core Laboratories (NYSE: CLB) has acquired Solintec, a leading Brazil-based integrated geological services company, to strengthen its presence in Brazil's oil and gas sector. This strategic acquisition enhances Core Lab's geological assessment capabilities for complex offshore pre-salt and onshore projects by combining Solintec's in-country mineralogic and sedimentary analysis with Core Lab's proprietary dual-energy tomography. The move aligns with Core Lab's investment strategy in key growth markets, capitalizing on Brazil's emergence as a leading non-OPEC producer.
Core Labs Sets Q2 Earnings Date: CEO and CFO to Present Latest Oil Services Performance
Core Laboratories (NYSE: CLB) has scheduled its second quarter 2025 earnings conference call for July 24, 2025, at 7:30 a.m. CDT, with the earnings release on July 23, 2025, after market close. CEO Larry Bruno, CFO Chris Hill, and SVP Gwen Gresham will discuss the financial and operational results. Investors can access the webcast and replay on the company's website.
Is There An Opportunity With Core Laboratories Inc.'s (NYSE:CLB) 49% Undervaluation?
Core Laboratories (NYSE:CLB) appears 49% undervalued with a fair value projected at US$23.89 based on a 2-stage Discounted Cash Flow (DCF) model, significantly higher than its current share price of US$12.26. The analysis, which relies on analyst estimates and a 7.6% discount rate, suggests a substantial discount to its intrinsic value. Investors should consider the assumptions behind this valuation and other factors like financial health and future earnings.
Core Laboratories opens unconventional core analysis lab in Saudi Arabia
Core Laboratories Inc. has opened a new Unconventional Core Analysis Laboratory in Saudi Arabia in collaboration with Abdulla Fouad Group. This facility will provide advanced core and fluid analysis services specifically for unconventional reservoirs using proprietary instrumentation and technologies like dual energy CT-scanning and NMR. The initiative aims to optimize the appraisal, development, and production of unconventional fields in the Middle East.
CORE LABORATORIES AND HALLIBURTON ANNOUNCE COLLABORATION TO INTEGRATE DIGITAL ROCK CAPABILITIES WITH LABORATORY MEASURED DATA
Halliburton Company and Core Laboratories Inc. have announced a strategic collaboration in the U.S. to integrate digital rock capabilities with laboratory measured data, significantly reducing the delivery time for comprehensive digital rock data solutions. This partnership combines Core Lab's expertise in reservoir description with Halliburton's pore-scale digital rock analysis to enhance the accuracy and innovation of digital rock characterization workflows. The collaboration aims to provide critical insights into reservoir assets much earlier, reducing risks and uncertainties for clients.
CORE LAB ANNOUNCES PROPOSED REDOMESTICATION TO THE UNITED STATES
Core Laboratories N.V. announced a proposed plan to reorganize its corporate structure by redomesticating its parent company from the Netherlands to the United States. This move aims to simplify the corporate structure, improve operational efficiencies, and reduce administrative costs, ultimately enhancing shareholder value. The redomestication will involve a merger and migration process, resulting in Core Laboratories Inc. (Delaware) becoming the ultimate parent company, with existing shareholders receiving one share in the new entity for each share held.
Core Laboratories (CLB) Expected to Beat Earnings Estimates: Should You Buy?
Core Laboratories (CLB) is anticipated to surpass its earnings estimates for the quarter ending September 2022, driven by a positive Earnings ESP and a Zacks Rank #2 (Buy). While revenue is expected to increase year-over-year, EPS is projected to see a decline. The article suggests that stocks with this combination of factors often lead to positive earnings surprises.
9 Undervalued Stocks in Top-Performing Sectors
This article identifies nine undervalued stocks across the top-performing sectors of energy, technology, and real estate. Morningstar analysts highlight companies like RingCentral, Ventas, and TechnipFMC, providing insights into their market positions and growth prospects. The analysis specifically notes that while technology and real estate tend to be overvalued, energy stocks remain largely undervalued.
Recon Confirms “Oil Zones” in Namibia, But Doesn’t say: ”Commercial Discovery”
Reconnaissance Energy Africa Ltd. (ReconAfrica) has released preliminary petrophysical analysis results for its first well (6-2 well) in the Kavango basin across Namibia and Botswana, identifying five potential conventional reservoir zones. The company emphasizes the establishment of a working hydrocarbon basin, but explicitly avoids claiming a "Commercial Discovery." The report details log and core analysis confirming 198 meters of net reservoir and highlights ongoing seismic operations and community engagement through solar-powered water wells.
Michael Croft Obituary - Waynesboro, VA
Michael Croft, 69, a renowned petroleum geologist, passed away on November 27, 2017. He had a distinguished career with Mobil Oil and later as a consultant, known for his mentorship and contributions to significant oil and gas projects. He is survived by his wife, Evelyn Marie DeGolyer Croft, his children, and sisters.
